<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04772963</url>
  </required_header>
  <id_info>
    <org_study_id>SSA_2021_3</org_study_id>
    <nct_id>NCT04772963</nct_id>
  </id_info>
  <brief_title>Genetics of Central Nervous System Arteriovenous Malformations (GENE-MAV)</brief_title>
  <acronym>GENE-MAV</acronym>
  <official_title>Genetics of Central Nervous System Arteriovenous Malformations (AVM): Genotype-Phenotype Correlation and Prognostic Impact on Patients With AVM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cerebral and medullary arteriovenous malformations (AVMs) are morphologically abnormal&#xD;
      vessels located on the surface or in the cerebral or medullary parenchyma. These vascular&#xD;
      lesions cause the arterial and venous networks to communicate pathologically, creating an&#xD;
      arteriovenous shunt.The prevalence of cerebral Cerebral and medullary AVMs in general&#xD;
      population is difficult to establish given the rarity of the condition. However, it is&#xD;
      estimated at around 1 per 10,000 inhabitants (0.01%). About 15-20% of the cerebral vascular&#xD;
      accidents are asymptomatic at the time of diagnosis. The occurrence of intracranial&#xD;
      haemorrhage is the most important prognostic factor because it is associated with a&#xD;
      significant morbidity and mortality. The management of an AVM is usually carried out in a&#xD;
      multidisciplinary way, combining interventional neuroradiology, neurosurgery and vascular&#xD;
      neurology.&#xD;
&#xD;
      The genetic, molecular and cellular mechanisms that cause vascular malformations of the&#xD;
      central nervous system are partially known. Several recent research works highlight mutations&#xD;
      in the RAS-MAPK or MAPK-ERK signalling pathway in AVMs. In cases of cerebral AVMs considered&#xD;
      to be sporadic, a somatic KRAS/BRAF mutation has recently been demonstrated in tissue samples&#xD;
      of operated AVMs.&#xD;
&#xD;
      Except in the case of Hereditary Haemorrhagic Telangiectasia (HHT or Rendu-Osler-Weber&#xD;
      syndrome), the influence of genetic damage on the prognosis of AVM is poorly known. It is&#xD;
      also interesting to note that genetic screening is not routinely performed in patients with&#xD;
      cerebro-medullary AVMs and that therefore the prevalence of these clinical entities in&#xD;
      patients with AVMs is not known.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2026</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genetic mutation</measure>
    <time_frame>limit of 12 month</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Arteriovenous Malformations</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>During the arteriography a peripheral venous sampling</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The recruited population will be index cases with cerebrovascular cerebral vascular&#xD;
        malformations treated in the participating centres&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with a vascular malformation of the cerebral or medullary identified on&#xD;
             diagnostic imaging (angio-CT, angio-MRI or diagnostic angiography) for which clinical&#xD;
             monitoring alone or intervention (endovascular treatment, surgery or radiosurgery) is&#xD;
             planned in the centres participating in the research.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant, parturient or breastfeeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stanislas Smajda</last_name>
    <phone>0148036454</phone>
    <email>ssmajda@for.paris</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Am√©lie Yavchitz</last_name>
    <phone>0148036454</phone>
    <email>ayavchitz@for.paris</email>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>February 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioma</mesh_term>
    <mesh_term>Arteriovenous Malformations</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

